Two summer announcements from the British Business Bank sit oddly next to each other once you line up the figures. In July, the Bank committed €65m, roughly £55.6m, to Highland Europe's sixth growth equity fund, a vehicle that closed at €1.1bn and will back software, AI, cybersecurity, fintech, data and consumer technology companies through to pre-IPO stage. In the same window it put £25m into Alchemab Therapeutics, a Cambridge biotech extending its Series A round, and €25m into EQT Life Sciences' latest medtech fund, a vehicle with total capital of €216m. Months earlier it had made its largest single fund commitment to date, £100m, to help Apposite Capital reach first close on a healthcare-dedicated growth fund. Read individually, each is a straightforward funding story. Read together, they describe something closer to a structural pattern in how the state prices its own health ambitions.

The Bank does not lack conviction about life sciences. Its own investment director for the sector has said publicly that the need for scale-up funding is especially pronounced there, and that a shortage of later-stage funds has pushed promising British companies towards premature or under-valued exits abroad. That is precisely the diagnosis behind the Apposite and EQT commitments. Yet the vehicles built to answer it remain an order of magnitude smaller than the generalist growth funds the Bank backs in the same year. A software or fintech scaleup with Highland Europe access sits inside a fund almost five times the size of the entire EQT medtech vehicle. A life sciences company approaching the same growth inflection is routed into funds measured in the tens or low hundreds of millions, however deliberately assembled.

This matters to the NHS well beyond the abstractions of industrial strategy. Ministers have made life sciences one of eight named growth sectors and have talked up AI-enabled diagnostics, digital pathways and data platforms as the mechanism through which an overstretched service finally gains headroom. Trusts are being asked to commission and integrate technology at a pace that assumes a healthy domestic supply of mature health-tech vendors capable of delivering at scale, not perpetual early-stage promise. But a company that cannot raise growth capital at home on terms comparable to its software counterparts faces a familiar choice: sell early to an overseas acquirer, relocate its later funding rounds, or simply stay smaller than the market opportunity would otherwise allow. Each of those outcomes narrows the pool of companies the NHS can eventually contract with on its own terms.

There is a direct line here to a tension already visible inside NHS digital transformation, where large procurement decisions keep landing with a small number of established, often foreign, technology providers. Vendor concentration around firms such as Epic or Palantir is not simply a preference for proven systems. It reflects, in part, the absence of a deep bench of scaled domestic alternatives that have been through the kind of growth financing that turns a promising clinical-stage or health-data company into an operationally mature supplier. If the growth capital available to health technology companies remains structurally smaller than that available to a fintech or cybersecurity peer, the NHS should expect that concentration to persist regardless of how many digital strategies are published.

None of this suggests the Bank is neglecting life sciences. Its recent activity, including its largest ever direct investment in a biotech company, argues the opposite. The more uncomfortable point is that recognising a funding gap and building dedicated vehicles to address it is not the same as closing the scale disparity itself. Until life sciences and health-tech growth funds can operate on something closer to the same financial footing as their generalist counterparts, the government's own ambitions for an NHS supplied by scaled domestic technology companies will keep outrunning the capital structures meant to deliver them.